Phio Pharmaceuticals Corp. — Director's Dealing 2024

Aug 15, 2024

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Phio Pharmaceuticals Corp. (PHIO)
CIK: 0001533040
Period of Report: 2024-08-13

Reporting Person: Infarinato Robert M. (VP, Chief Financial Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2024-08-13	Common stock, $0.0001 par value	A	8000	—	Acquired	8000	Direct

Footnotes

F1: Represents shares underlying a restricted stock unit, which shares will vest in three equal annual installments commencing on the first anniversary of the grant date.

F2: Includes shares of common stock underlying unvested restricted stock units.